<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601142</url>
  </required_header>
  <id_info>
    <org_study_id>BeijingTH-YLJD-202001</org_study_id>
    <nct_id>NCT04601142</nct_id>
  </id_info>
  <brief_title>Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism</brief_title>
  <official_title>Study on the Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica and Gene Polymorphism: a Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aims of this study are to observe the correlation between ABCB1、VDR、TBX21、NR3C1 and other&#xD;
      gene polymorphisms and the effect of glucocorticoid shock therapy on neuromyelitis optica.&#xD;
      Investigators plan to include patients with neuromyelitis optica who will receive&#xD;
      glucocorticoid shock therapy prospectively. The patients are divided into glucocorticoid&#xD;
      sensitive (GS) group and glucocorticoid resistance (GR) group according to the change of&#xD;
      central vision after treatment. Patients' clinical data will be collected and blood samples&#xD;
      are needed for single nucleotide polymorphism (SNP) typing test. Through statistical&#xD;
      analysis, the data differences between GS group and GR group were compared, and the effects&#xD;
      of clinical indexes and gene polymorphisms on the efficacy of glucocorticoid shock therapy in&#xD;
      the treatment of neuromyelitis optica should be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the change of best corrected visual acuity (BCVA)</measure>
    <time_frame>3 day after the treatment of methylprednisolone pulse therapy</time_frame>
    <description>Test BCVA before and after the treatment of methylprednisolone pulse therapy, and calculate the change value</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Glucocorticoid Resistance</condition>
  <condition>Gene</condition>
  <condition>Neuromyelitis Optica</condition>
  <arm_group>
    <arm_group_label>glucocorticoid sensitive (GS) group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>glucocorticoid resistance (GR) group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ</description>
    <arm_group_label>glucocorticoid resistance (GR) group</arm_group_label>
    <arm_group_label>glucocorticoid sensitive (GS) group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        New diagnosis NMO patients who plan to receive methylprednisolone pulse therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of neuromyelitis optica&#xD;
&#xD;
          -  Chinese Han nationality, gender is unlimited;&#xD;
&#xD;
          -  Must be able to accept methylprednisolone pulse therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other optic nerve diseases, such as ischemic, compressive, invasive, traumatic, toxic&#xD;
             and nutritional metabolic, hereditary optic neuropathy;&#xD;
&#xD;
          -  Visual path and central lesion on optic chiasma;&#xD;
&#xD;
          -  Other eye diseases, such as anterior segment lesions, retinopathy, macular lesions,&#xD;
             ametropia, glaucoma, etc;&#xD;
&#xD;
          -  Non-organic visual impairment;&#xD;
&#xD;
          -  Treated with glucocorticoid in two weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yu yang Dai, PhD</last_name>
    <phone>010-58268486</phone>
    <phone_ext>86</phone_ext>
    <email>daiyy1991@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Yang Dai, PhD</last_name>
      <phone>010-58268486</phone>
      <phone_ext>86</phone_ext>
      <email>daiyy1991@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

